# A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis

> **NCT00441103** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 180 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Rebif® New Formulation (IFN-beta-1a, RNF)
- **DRUG:** Placebo
- **DRUG:** Rebif® New Formulation (IFN-beta-1a, RNF)

## Key facts

- **NCT ID:** NCT00441103
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-11
- **Final completion:** 2009-02
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2014-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441103, "A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00441103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*